文献速递脑血管病

先进神经血管通路导管系统联合支架取栓器治疗急性缺血性卒中的临床结果(SOLONDA)

Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA).
PubMed 文献 · Stroke · 2022-04-01

SOLONDA是一项前瞻性、开放、单臂、多中心试验,评估先进神经血管通路(ANA)取栓系统联合支架取栓器治疗前循环闭塞的安全性与有效性。主要终点为意向治疗人群中救援治疗前使用ANA装置联合支架取栓器≤3次通过实现成功再灌注(mTICI 2b-3),预设非劣效于HERMES性能终点。入组74例后中期分析因安全性和性能目标达到而终止招募。

要点

  • 救援治疗前≤3次通过成功再灌注率为60/72(83.3% [95% CI, 74.7%-91.9%])。
  • 非劣效性确认后(P<0.01),ANA装置在≤3次通过成功再灌注率上亦显示优效性(P=0.02)。
  • 90天良好功能结局(mRS 0-2)率为57.5%(95% CI, 46.2%-68.9%),严重器械相关不良事件率为1.4%。

核心结论

  • 在该临床经验中,ANA装置实现了高比例的完全再通,具有初步良好的安全性特征和有利的90天临床结局。

研究设计与样本

  • SOLONDA为前瞻性、开放、单臂、多中心试验,主要结局由独立核心实验室盲法评估。
  • 纳入症状发作8小时内就诊的前循环血管闭塞患者。
  • 主要终点为意向治疗人群中救援治疗前使用ANA装置联合支架取栓器≤3次通过实现成功再灌注(mTICI 2b-3)。
  • 主要预设分析为对照HERMES中观察到的性能终点进行非劣效性检验。
  • 入组74例患者后进行中期分析,试验指导委员会因安全性和性能目标达到而决定终止招募。

主要发现

  • 平均年龄71.6岁(SD 8.9),女性占46.6%,入院时美国国立卫生研究院卒中量表评分中位数14分(四分位距10-19)。
  • 救援治疗前≤3次通过成功再灌注率为60/72(83.3% [95% CI, 74.7%-91.9%]),完全再灌注(mTICI 2c-3)率为60%(95% CI, 48.4%-71.1%;43/72例)。
  • 非劣效性确认后(P<0.01),ANA装置在≤3次通过成功再灌注率上亦显示优效性(P=0.02)。
  • 首过成功再通率为55.6%(95% CI, 44.1%-67.0%),首过完全再通率为38.9%(95% CI, 27.6%-50.1%)。
  • 获得mTICI 2b-3的救援治疗需要12/72例(17%)患者;90天良好功能结局(mRS 0-2)率为57.5%(95% CI, 46.2%-68.9%),极好功能结局(mRS 0-1)率为45.2%(95% CI, 33.8%-56.6%);严重器械相关不良事件率为1.4%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Advanced Neurovascular Access (ANA) thrombectomy system is a novel stroke thrombectomy device comprising a self-expanding funnel designed to reduce clot fragmentation by locally restricting flow while becoming as wide as the lodging artery. Once deployed, the ANA device allows distal aspiration combined with a stent retriever to mobilize the clot into the funnel where it remains copped during extraction. We investigated the safety and efficacy of ANA catheter system. METHODS: SOLONDA (Solitaire in Combination With the ANA Catheter System as Manufactured by Anaconda) was a prospective, open, single-arm, multicenter trial with blinded assessment of the primary outcome by an independent core lab. Patients with anterior circulation vessel occlusion admitted within 8 hours from symptom onset were eligible. The primary end point was successful reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3) with ≤3 passes of the ANA device in combination with stent retriever, before the use of rescue therapy in the intention to treat population. Primary predefined analysis was noninferiority as compared to the performance end point observed in HERMES (High Effective Reperfusion Using Multiple Endovascular Devices). RESULTS: After enrollment of 74 patients, an interim analysis was conducted, and the trial Steering Committee decided to terminate recruitment due to safety and performance objectives were reached. Mean age was 71.6 (SD 8.9) years, 46.6% women and median National Institutes of Health Stroke Scale on admission 14 (interquartile range, 10-19). Successful reperfusion within 3 passes before rescue therapy was achieved in 60/72 (83.3% [95% CI, 74.7%-91.9%]) with a rate of complete reperfusion (modified Thrombolysis in Cerebral Infarction score 2c-3) of 60% (95% CI, 48.4%-71.1%; 43/72 patients). After noninferiority was confirmed (P<0.01), the ANA device also showed superiority in the rate of successful reperfusion with ≤3 passes (P=0.02). First-pass successful recanalization rate was 55.6% (95% CI, 44.1%-67.0%), with a first-pass complete recanalization rate of 38.9% (95% CI, 27.6%-50.1%). Rescue therapy to obtain a modified Thrombolysis in Cerebral Infarction score 2b-3 was needed in 12/72 (17%) patients. At 90 days, the rate of favorable functional outcome (modified Rankin Scale score 0-2) was 57.5% (95% CI, 46.2%-68.9%), and the rate of excellent functional outcome (modified Rankin Scale score 0-1) was 45.2% (95% CI, 33.8%-56.6%). The rate of severe adverse device related was 1.4%. CONCLUSIONS: In this clinical experience, the ANA device achieved a high rate of complete recanalization with a preliminary good safety profile and favorable 90 days clinical outcomes. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04095767.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Requena M, Ribo M, Zamarro J, et al. Clinical Results of the Advanced Neurovascular Access Catheter System Combined With a Stent Retriever in Acute Ischemic Stroke (SOLONDA). Stroke. 2022. PMID: 35360928. doi:10.1161/STROKEAHA.121.037577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。